ArticleOPEN ACCESS

Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702

Journal of Medical Economics
DOI: 10.1080/13696998.2017.1360310
0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Patel, J., Zhao, X., Shah, D., Alhussain, K., & Kamal, K. (2017, November 2). Re: Saint-Laurent Thibault C, Moorjaney D, Ganz ML, et al. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States. J Med Econ 2017;20:692-702. Journal of Medical Economics. Taylor and Francis Ltd. https://doi.org/10.1080/13696998.2017.1360310

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free